Edap Tms Sa ADR (EDAP) 2.95 $EDAP EDAP Installs
Post# of 273254
EDAP Installs Ablatherm Robotic(R) HIFU at Leading Academic Medical Center
GlobeNewswire - Mon Sep 12, 7:30AM CDT
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the signature of a contract for the installation of Ablatherm Robotic HIFU at the renowned Duke University Hospital located in Durham, North Carolina.
EDAP: 2.95 (+0.01)
EDAP TMS to Present at the 18th Annual Rodman and Renshaw Global Investment Conference
GlobeNewswire - Tue Sep 06, 7:30AM CDT
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that Marc Oczachowski, Chief Executive Officer of EDAP TMS, is scheduled to present at the 18 Annual Rodman & Renshaw Global Investment Conference being held September 11-13, 2016 at the Lotte New York Palace Hotel in New York, NY.
EDAP: 2.95 (+0.01)
EDAP Reports 69% Growth in HIFU Revenues and Operating Profit for First Half 2016
GlobeNewswire - Thu Aug 25, 6:00AM CDT
-- Total EDAP revenue up 20.4% year-over-year in the first six months of 2016
EDAP: 2.95 (+0.01)
EDAP to Report Second Quarter 2016 Financial Results on August 25, 2016
GlobeNewswire - Thu Aug 11, 7:30AM CDT
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that it plans to release financial results for the second quarter ended June 30, 2016 on Thursday, August 25, 2016, during pre-market hours.
EDAP: 2.95 (+0.01)
EDAP First Quarter 2016 Revenue Increases 40% Year-over-Year to EUR8.7 Million
GlobeNewswire - Wed May 18, 6:00AM CDT
-- First quarter 2016 HIFU Division revenue increased 102% year-over-year
EDAP: 2.95 (+0.01)
EDAP to Report First Quarter 2016 Results on May 18, 2016
GlobeNewswire - Tue May 10, 7:30AM CDT
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that it plans to release financial results for the first quarter ended March 31, 2016, on May 18, 2016, during pre-market hours.
EDAP: 2.95 (+0.01)
EDAP Announces Presentations and Live Demonstrations of Ablatherm(R) Robotic HIFU at 2016 American Urology Association Annual Meeting, May 6-10, 2016
GlobeNewswire - Wed May 04, 7:30AM CDT
Company to Participate in Two Plenary Sessions and Five Poster Sessions
EDAP: 2.95 (+0.01)
EDAP Receives Brazilian Regulatory Approval for Focal One(R) HIFU Device
GlobeNewswire - Thu Apr 28, 7:30AM CDT
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that The Brazilian Health Surveillance Agency (Anvisa) has approved Focal One for sale in Brazil.
EDAP: 2.95 (+0.01)
Houston Methodist Hospital, Houston, TX Acquires and Installs EDAP's Ablatherm(R) Robotic HIFU
GlobeNewswire - Mon Apr 25, 7:36AM CDT
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the sale and installation of Ablatherm Robotic HIFU at Houston Methodist Hospital, Houston, Texas. The hospital is the first location in Texas to install EDAP's noninvasive HIFU device for the ablation of prostate tissue.
EDAP: 2.95 (+0.01)
EDAP's Ablatherm(R) Robotic HIFU Deployed by HIFU Solution
GlobeNewswire - Mon Apr 18, 7:30AM CDT
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the first prostate ablation treatments performed in Orlando, Florida, using the Company's FDA-cleared Ablatherm Robotic HIFU.
EDAP: 2.95 (+0.01)
EDAP TMS SA Closes $11.5 Million Registered Direct Offering
GlobeNewswire - Thu Apr 14, 2:15PM CDT
Positions EDAP to Accelerate U.S. Sales and Marketing Expansion for HIFU
EDAP: 2.95 (+0.01)
First Prostate Ablation Treatments Performed Using EDAP's FDA Approved Ablatherm(R) Robotic HIFU at Sylvester Comprehensive Cancer Center, in Miami, Florida
GlobeNewswire - Mon Jan 25, 7:30AM CST
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the first prostate ablation treatments performed at Sylvester Comprehensive Cancer Center, Miami, using FDA approved Ablatherm Robotic HIFU. Sylvester Center will serve as the Ablatherm HIFU training and proctoring center for the U.S. East Coast and a door opened to the South American Market.
EDAP: 2.95 (+0.01)
EDAP Announces Results of World's First Focal HIFU Trial
GlobeNewswire - Tue Jan 19, 7:30AM CST
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the publication of long term results of Ablatherm Focal HIFU in the peer reviewed journal "Prostate Cancer and Prostatic Diseases," part of the Nature Publishing Group.
EDAP: 2.95 (+0.01)
EDAP Reports Sale of Ablatherm Robotic HIFU to Sylvester Comprehensive Cancer Center
GlobeNewswire - Mon Dec 21, 7:30AM CST
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the sale of an Ablatherm Robotic HIFU device to Sylvester Comprehensive Cancer Center, part of UHealth - the University of Miami Health System.
EDAP: 2.95 (+0.01)
EDAP Receives Russian Regulatory Approval for Focal One(R) HIFU Device
GlobeNewswire - Fri Dec 11, 7:30AM CST
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that Russia's Federal Service for Surveillance in Healthcare (Roszdravnadzor) has approved Focal One for sale in Russia. Russia is currently the largest market for EDAP's Ablatherm(R) robotic HIFU technology.
EDAP: 2.95 (+0.01)
EDAP Reports Installation of Ablatherm Robotic HIFU at University of Southern California
GlobeNewswire - Wed Dec 09, 7:30AM CST
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the first installation of Ablatherm Robotic HIFU at University of Southern California, Keck Medicine of USC, which will become the first reference and training center for Ablatherm Robotic HIFU in the U.S.
EDAP: 2.95 (+0.01)
Positive Outcomes From Prostate Cancer Hemiablation Study With EDAP Ablatherm Robotic HIFU Presented at 109th French Urology Congress
GlobeNewswire - Tue Nov 24, 10:00AM CST
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced data from a multicenter trial demonstrating encouraging outcomes of focal HIFU as a new treatment strategy for patients with unilateral localized prostate cancer.
EDAP: 2.95 (+0.01)
Direction of Market Influences - Research on EVINE Live, hhgregg, Abeona Therapeutics and Edap Tms
ACCESSWIRE - Mon Nov 23, 7:05AM CST
NEW YORK, NY / ACCESSWIRE / November 23, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: EVINE Live Inc. (NASDAQ: EVLV), hhgregg Inc. (NYSE: HGG), Abeona Therapeutics Inc. (NASDAQ: ABEO) and Edap Tms SA (NASDAQ: EDAP). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
EDAP: 2.95 (+0.01), HGG: 1.91 (+0.03), EVLV: 2.31 (unch), ABEO: 6.29 (-0.10)
EDAP Reports Third Quarter 2015 Financial Results and Operational Update
GlobeNewswire - Wed Nov 18, 4:45PM CST
-- Obtained FDA clearance for Ablatherm(R) HIFU in November
EDAP: 2.95 (+0.01)
Masimo SET Technology Picked by India's Cloudnine Hospital
Zacks Equity Research - Zacks Investment Research - Tue Nov 17, 1:50PM CST
Masimo Corporation (MASI) recently announced that India-based Cloudnine Hospital Group has taken up Masimo SET technology to monitor infants suffering from Critical Congenital Heart Disease (CCHD).
ISRG: 710.22 (-7.98), BABY: 43.99 (-0.39), MASI: 59.77 (-0.55), EDAP: 2.95 (+0.01)